Global Drug Modeling Software Market

Drug Modeling Software Comprehensive Study by Application (Laboratory, Research Institutes, Educational Institutes, Others), Deployment (Cloud-based, On-premise), Features (Disease Modeling, Predictive Analysis, Cellular Simulation, Medical Imaging, Others) Players and Region - Global Market Outlook to 2028

Drug Modeling Software Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Drug modeling software is used in developing and modeling pharmaceutical drugs, it helps in providing effectiveness in drug discovery and treating a particular disease. This software automates the whole process of drug discovery including modeling, development, testing, etc as it uses innovative technology. It analyses the molecular modeling of genes, gene expressions, analyses the sequence and 3D structure of proteins. It is widely used by researchers and scientists in research institutes and laboratories.This growth is primarily driven by Growing Research and Development in Drug Discovery .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Internet Software & Services sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Dassault Systemes (BIOVIA) (United States), AutoDock (Germany), Schrodinger, Inc. (United States), ArgusLab (United States), Crown Bioscience Inc. (United States), Nimbus Therapeutics, LLC (United States), Genedata AG (Switzerland), Acellera (Spain), Leadscope, Inc. (United States) and Certara, Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 6th August 2020, Dassault Systemes Partners in Drug Discovery Hackathon 2020. DDH2020 aims to establish an open innovation model for in silico drug discovery against COVID-19. Dassault Systèmes will offer access to BIOVIA Discovery Studio to hackathon participants. Partnership is part of the company’s commitment to empowering Life Sciences companies and the broader healthcare ecosystem in the fight against the virus.
On 24th June 2020, Certara, Inc., the global leader in biosimulation, announced the launch of version 8.3 of its Phoenix platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.3 delivers new features to drive efficiencies and quality and save valuable time. and On 8th January 2020, Schrodinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.

Influencing Trend:
Increasing Use of Drug Modeling Software in Laboratories and Research Institutes

Market Growth Drivers:
Growing Research and Development in Drug Discovery and Demand for Automation in the Drug Chemistry for Effective Results

Challenges:
Problems with Unexpected Network Connectivity

Restraints:
Requirements of Professional Skills in Drug Modeling Software and Regulatory Compliance with Drug Modeling Software

Opportunities:
Technological Upgradation in Drug Modeling Software and Integration of Artificial Intelligence in Drug Modeling Software

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Drug Modeling Software Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Drug Modeling Software Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Drug Modeling Software players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Drug Modeling Software Study Sheds Light on
— The Drug Modeling Software Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Drug Modeling Software industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Drug Modeling Software industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Laboratory
  • Research Institutes
  • Educational Institutes
  • Others
By Deployment
  • Cloud-based
  • On-premise

By Features
  • Disease Modeling
  • Predictive Analysis
  • Cellular Simulation
  • Medical Imaging
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Research and Development in Drug Discovery
      • 3.2.2. Demand for Automation in the Drug Chemistry for Effective Results
    • 3.3. Market Challenges
      • 3.3.1. Problems with Unexpected Network Connectivity
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Drug Modeling Software in Laboratories and Research Institutes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Modeling Software, by Application, Deployment, Features and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drug Modeling Software (Value)
      • 5.2.1. Global Drug Modeling Software by: Application (Value)
        • 5.2.1.1. Laboratory
        • 5.2.1.2. Research Institutes
        • 5.2.1.3. Educational Institutes
        • 5.2.1.4. Others
      • 5.2.2. Global Drug Modeling Software by: Deployment (Value)
        • 5.2.2.1. Cloud-based
        • 5.2.2.2. On-premise
      • 5.2.3. Global Drug Modeling Software by: Features (Value)
        • 5.2.3.1. Disease Modeling
        • 5.2.3.2. Predictive Analysis
        • 5.2.3.3. Cellular Simulation
        • 5.2.3.4. Medical Imaging
        • 5.2.3.5. Others
      • 5.2.4. Global Drug Modeling Software Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Drug Modeling Software: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dassault Systemes (BIOVIA) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AutoDock (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Schrodinger, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ArgusLab (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Crown Bioscience Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Nimbus Therapeutics, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genedata AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Acellera (Spain)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Leadscope, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Certara, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drug Modeling Software Sale, by Application, Deployment, Features and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drug Modeling Software (Value)
      • 7.2.1. Global Drug Modeling Software by: Application (Value)
        • 7.2.1.1. Laboratory
        • 7.2.1.2. Research Institutes
        • 7.2.1.3. Educational Institutes
        • 7.2.1.4. Others
      • 7.2.2. Global Drug Modeling Software by: Deployment (Value)
        • 7.2.2.1. Cloud-based
        • 7.2.2.2. On-premise
      • 7.2.3. Global Drug Modeling Software by: Features (Value)
        • 7.2.3.1. Disease Modeling
        • 7.2.3.2. Predictive Analysis
        • 7.2.3.3. Cellular Simulation
        • 7.2.3.4. Medical Imaging
        • 7.2.3.5. Others
      • 7.2.4. Global Drug Modeling Software Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Modeling Software: by Application(USD Million)
  • Table 2. Drug Modeling Software Laboratory , by Region USD Million (2017-2022)
  • Table 3. Drug Modeling Software Research Institutes , by Region USD Million (2017-2022)
  • Table 4. Drug Modeling Software Educational Institutes , by Region USD Million (2017-2022)
  • Table 5. Drug Modeling Software Others , by Region USD Million (2017-2022)
  • Table 6. Drug Modeling Software: by Deployment(USD Million)
  • Table 7. Drug Modeling Software Cloud-based , by Region USD Million (2017-2022)
  • Table 8. Drug Modeling Software On-premise , by Region USD Million (2017-2022)
  • Table 9. Drug Modeling Software: by Features(USD Million)
  • Table 10. Drug Modeling Software Disease Modeling , by Region USD Million (2017-2022)
  • Table 11. Drug Modeling Software Predictive Analysis , by Region USD Million (2017-2022)
  • Table 12. Drug Modeling Software Cellular Simulation , by Region USD Million (2017-2022)
  • Table 13. Drug Modeling Software Medical Imaging , by Region USD Million (2017-2022)
  • Table 14. Drug Modeling Software Others , by Region USD Million (2017-2022)
  • Table 15. South America Drug Modeling Software, by Country USD Million (2017-2022)
  • Table 16. South America Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 17. South America Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 18. South America Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 19. Brazil Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 20. Brazil Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 21. Brazil Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 22. Argentina Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 23. Argentina Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 24. Argentina Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 25. Rest of South America Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 26. Rest of South America Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 27. Rest of South America Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 28. Asia Pacific Drug Modeling Software, by Country USD Million (2017-2022)
  • Table 29. Asia Pacific Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 31. Asia Pacific Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 32. China Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 33. China Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 34. China Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 35. Japan Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 36. Japan Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 37. Japan Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 38. India Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 39. India Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 40. India Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 41. South Korea Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 42. South Korea Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 43. South Korea Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 44. Taiwan Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 45. Taiwan Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 46. Taiwan Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 47. Australia Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 48. Australia Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 49. Australia Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 53. Europe Drug Modeling Software, by Country USD Million (2017-2022)
  • Table 54. Europe Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 55. Europe Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 56. Europe Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 57. Germany Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 58. Germany Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 59. Germany Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 60. France Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 61. France Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 62. France Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 63. Italy Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 64. Italy Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 65. Italy Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 66. United Kingdom Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 67. United Kingdom Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 68. United Kingdom Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 69. Netherlands Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 70. Netherlands Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 71. Netherlands Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 72. Rest of Europe Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 73. Rest of Europe Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 74. Rest of Europe Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 75. MEA Drug Modeling Software, by Country USD Million (2017-2022)
  • Table 76. MEA Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 77. MEA Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 78. MEA Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 79. Middle East Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 80. Middle East Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 81. Middle East Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 82. Africa Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 83. Africa Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 84. Africa Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 85. North America Drug Modeling Software, by Country USD Million (2017-2022)
  • Table 86. North America Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 87. North America Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 88. North America Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 89. United States Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 90. United States Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 91. United States Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 92. Canada Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 93. Canada Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 94. Canada Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 95. Mexico Drug Modeling Software, by Application USD Million (2017-2022)
  • Table 96. Mexico Drug Modeling Software, by Deployment USD Million (2017-2022)
  • Table 97. Mexico Drug Modeling Software, by Features USD Million (2017-2022)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Drug Modeling Software: by Application(USD Million)
  • Table 109. Drug Modeling Software Laboratory , by Region USD Million (2023-2028)
  • Table 110. Drug Modeling Software Research Institutes , by Region USD Million (2023-2028)
  • Table 111. Drug Modeling Software Educational Institutes , by Region USD Million (2023-2028)
  • Table 112. Drug Modeling Software Others , by Region USD Million (2023-2028)
  • Table 113. Drug Modeling Software: by Deployment(USD Million)
  • Table 114. Drug Modeling Software Cloud-based , by Region USD Million (2023-2028)
  • Table 115. Drug Modeling Software On-premise , by Region USD Million (2023-2028)
  • Table 116. Drug Modeling Software: by Features(USD Million)
  • Table 117. Drug Modeling Software Disease Modeling , by Region USD Million (2023-2028)
  • Table 118. Drug Modeling Software Predictive Analysis , by Region USD Million (2023-2028)
  • Table 119. Drug Modeling Software Cellular Simulation , by Region USD Million (2023-2028)
  • Table 120. Drug Modeling Software Medical Imaging , by Region USD Million (2023-2028)
  • Table 121. Drug Modeling Software Others , by Region USD Million (2023-2028)
  • Table 122. South America Drug Modeling Software, by Country USD Million (2023-2028)
  • Table 123. South America Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 124. South America Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 125. South America Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 126. Brazil Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 127. Brazil Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 128. Brazil Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 129. Argentina Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 130. Argentina Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 131. Argentina Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 132. Rest of South America Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 133. Rest of South America Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 134. Rest of South America Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 135. Asia Pacific Drug Modeling Software, by Country USD Million (2023-2028)
  • Table 136. Asia Pacific Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 137. Asia Pacific Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 138. Asia Pacific Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 139. China Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 140. China Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 141. China Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 142. Japan Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 143. Japan Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 144. Japan Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 145. India Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 146. India Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 147. India Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 148. South Korea Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 149. South Korea Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 150. South Korea Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 151. Taiwan Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 152. Taiwan Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 153. Taiwan Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 154. Australia Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 155. Australia Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 156. Australia Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 158. Rest of Asia-Pacific Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 160. Europe Drug Modeling Software, by Country USD Million (2023-2028)
  • Table 161. Europe Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 162. Europe Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 163. Europe Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 164. Germany Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 165. Germany Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 166. Germany Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 167. France Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 168. France Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 169. France Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 170. Italy Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 171. Italy Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 172. Italy Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 173. United Kingdom Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 174. United Kingdom Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 175. United Kingdom Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 176. Netherlands Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 177. Netherlands Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 178. Netherlands Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 179. Rest of Europe Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 180. Rest of Europe Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 181. Rest of Europe Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 182. MEA Drug Modeling Software, by Country USD Million (2023-2028)
  • Table 183. MEA Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 184. MEA Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 185. MEA Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 186. Middle East Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 187. Middle East Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 188. Middle East Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 189. Africa Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 190. Africa Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 191. Africa Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 192. North America Drug Modeling Software, by Country USD Million (2023-2028)
  • Table 193. North America Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 194. North America Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 195. North America Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 196. United States Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 197. United States Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 198. United States Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 199. Canada Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 200. Canada Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 201. Canada Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 202. Mexico Drug Modeling Software, by Application USD Million (2023-2028)
  • Table 203. Mexico Drug Modeling Software, by Deployment USD Million (2023-2028)
  • Table 204. Mexico Drug Modeling Software, by Features USD Million (2023-2028)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Modeling Software: by Application USD Million (2017-2022)
  • Figure 5. Global Drug Modeling Software: by Deployment USD Million (2017-2022)
  • Figure 6. Global Drug Modeling Software: by Features USD Million (2017-2022)
  • Figure 7. South America Drug Modeling Software Share (%), by Country
  • Figure 8. Asia Pacific Drug Modeling Software Share (%), by Country
  • Figure 9. Europe Drug Modeling Software Share (%), by Country
  • Figure 10. MEA Drug Modeling Software Share (%), by Country
  • Figure 11. North America Drug Modeling Software Share (%), by Country
  • Figure 12. Global Drug Modeling Software share by Players 2022 (%)
  • Figure 13. Global Drug Modeling Software share by Players (Top 3) 2022(%)
  • Figure 14. Global Drug Modeling Software share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Dassault Systemes (BIOVIA) (United States) Revenue, Net Income and Gross profit
  • Figure 17. Dassault Systemes (BIOVIA) (United States) Revenue: by Geography 2022
  • Figure 18. AutoDock (Germany) Revenue, Net Income and Gross profit
  • Figure 19. AutoDock (Germany) Revenue: by Geography 2022
  • Figure 20. Schrodinger, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Schrodinger, Inc. (United States) Revenue: by Geography 2022
  • Figure 22. ArgusLab (United States) Revenue, Net Income and Gross profit
  • Figure 23. ArgusLab (United States) Revenue: by Geography 2022
  • Figure 24. Crown Bioscience Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Crown Bioscience Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Nimbus Therapeutics, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 27. Nimbus Therapeutics, LLC (United States) Revenue: by Geography 2022
  • Figure 28. Genedata AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Genedata AG (Switzerland) Revenue: by Geography 2022
  • Figure 30. Acellera (Spain) Revenue, Net Income and Gross profit
  • Figure 31. Acellera (Spain) Revenue: by Geography 2022
  • Figure 32. Leadscope, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Leadscope, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Certara, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Certara, Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Global Drug Modeling Software: by Application USD Million (2023-2028)
  • Figure 37. Global Drug Modeling Software: by Deployment USD Million (2023-2028)
  • Figure 38. Global Drug Modeling Software: by Features USD Million (2023-2028)
  • Figure 39. South America Drug Modeling Software Share (%), by Country
  • Figure 40. Asia Pacific Drug Modeling Software Share (%), by Country
  • Figure 41. Europe Drug Modeling Software Share (%), by Country
  • Figure 42. MEA Drug Modeling Software Share (%), by Country
  • Figure 43. North America Drug Modeling Software Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Dassault Systemes (BIOVIA) (United States)
  • AutoDock (Germany)
  • Schrodinger, Inc. (United States)
  • ArgusLab (United States)
  • Crown Bioscience Inc. (United States)
  • Nimbus Therapeutics, LLC (United States)
  • Genedata AG (Switzerland)
  • Acellera (Spain)
  • Leadscope, Inc. (United States)
  • Certara, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 223 Pages 60 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drug Modeling Software Market Quantitative research analysis
Global Drug Modeling Software Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Drug Modeling Software Market are Dassault Systemes (BIOVIA) (United States), AutoDock (Germany), Schrodinger, Inc. (United States), ArgusLab (United States), Crown Bioscience Inc. (United States), Nimbus Therapeutics, LLC (United States), Genedata AG (Switzerland), Acellera (Spain), Leadscope, Inc. (United States) and Certara, Inc. (United States) etc.
Laboratory segment in Global market to hold robust market share owing to "Growing Research and Development in Drug Discovery ".

Know More About Global Drug Modeling Software Market Report?

Have a Query? Click Here

Other Related Reports

Cognitive Cloud Computing Comprehensive Study by Deployment Type (On-Premise, Cloud), Organization Size (SMEs, Large enterprises), Technology (Natural Language Processing, Machine Learning, Automate...
$ 3650
Dark Web Intelligence Comprehensive Study by Deployment Mode (SaaS platform, On-premises, Cloud based), Business Model (Sell/ Purchase, Communication, Payments, Others), Content (Unstructured, Unlink...
$ 3750
Limousine Software Comprehensive Study by Application (Small and Medium Businesses (SMBs), Large Enterprise), Pricing Option (Subscription Based {Annual, Monthly}, One Time License), Deployment (On-c...
$ 3650
Credit Insurance Software Comprehensive Study by Deployment Mode (Cloud, On-Premise), Enterprise Size (Small and Medium Size Enterprise, Large Enterprise), End User (Brokers, Policy Holders, Other...
$ 3500
Document Creation and Assembly Software Comprehensive Study by Pricing Option (Free Trial, Monthly Subscription, Annual Subscription, One Time License), End Use Industry (Legal/Law Firm, BFSI, Health...
$ 3750
Online Advocacy Platform Comprehensive Study by Application (Advocate Management, Campaign Management, Customer Advocacy, Engagement Analytics, Non-Profit Advocacy, Rewards Management, Others), Enter...
$ 3650